2 September 2014

Update: The Danish HCP Affiliation/Sunshine Act

On 20 May 2014 the Danish Parliament passed an act, which will transform how pharmaceutical and medical device companies may interact with Danish healthcare professionals. Furthermore, the act - which enters into force on 1 November 2014 - provides for a much higher degree of transparency. Pharmaceutical and medical device companies conducting  business in Denmark must prepare themselves for a novel regulatory landscape.

The Danish HCP Sunshine Act is comprised by two separate regimes and principles, covering

  • companies' affiliation with HCPs; and
  • companies' provision of economic benefits to HCPs.


Under the existing Danish regulations, medical doctors, dentists and pharmacists must obtain a prior permit from the Danish Health and Medicines Authority to have a professional and/or economic affiliation with a pharmaceutical company. 

The Danish HCP Sunshine Act will expand the scope of application of the existing regulations on two points:

  • Affiliation with medical device companies is included; and
  • Nurses are included (but only in relation to affiliation with medical device companies).

Furthermore, the permission regime is abolished for certain forms of professional and economic affiliation if the affiliation is considered to be useful from a professional point of view and with only a slight risk of affecting the HCP's impartiality (examples are "lecturing" and "research"). Instead, the HCP is "merely" to report the cooperation to the Danish Health and Medicines Authority. However, a permission regime will apply to pharmaceutical and medical device industry affiliation which is characterised by "advisory" services, e.g. participation in advisory boards. 

It is important to note that it is the duty of the HCP to either apply for the Authority's permission or to notify the Authority. 

The companies' duties are:

  • to inform the HCPs of the HCPs' duty to either apply for the Danish Health and Medicines Authority's prior permission or to notify the Authority. Companies that do not observe this requirement may be subject to fines;
  • to forward an annual report to the Danish Health and Medicines Authority comprising details about any and all HCPs, who have been affiliated with the company within the preceding calendar year.

On the basis of the HCP's application/notification, the Danish Health and Medicines Authority will disclose information available to the general public, including competitors, containing the following information:

  • the name/identity of the HCP;
  • the name/identity of the company;
  • a description of the affiliation and its duration; and
  • the combined value of all remuneration paid by the company to the HCP during a calendar year.

As a finishing remark, it is worth noting that the Danish HCP Sunshine Act will introduce an application scheme for HCPs' future acquisitions of shares/stocks (or other types of ownership) in companies marketing pharmaceutical products or medical devices. However, HCPs may acquire shares of a value not exceeding DKK 200,000 (~ EUR 26,850) from each company, given that the Danish Health and Medicines Authority is notified of the ownership. The Danish Health and Medicines Authority will make information of such stockholdings public.

Economic benefits

It is important to note that, in relation to economic benefits, the term HCP is not limited to doctors, dentists, nurses and pharmacists but covers a much wider range of professionals, including (but not limited to) radiographs, midwives and senior employees in retail shops selling medical devices. 

The Danish HCP Sunshine Act will not make material amendments to the executive order currently applicable to pharmaceutical companies, apart from abolishing the provision of courtesy gifts to HCPs and abolishing the use of competitions/raffles when promoting pharmaceutical products towards HCPs.

Instead, the major change is that medical device companies will be subject to the same requirements as pharmaceutical companies. It follows that medical device companies may no longer provide economic benefits to HCPs, save for the explicit derogations which will be provided. These derogations will be set out in an executive order. The executive order has not yet been passed, but a draft has just been published for public consultation.

According to the drafts, derogations will be made for e.g. providing modest gifts (but not courtesy gifts) to HCPs as well as providing travel and accommodation (in relation to HCPs' participation in events of a professional nature). However, and notably, a similar derogation for lending equipment to HCPs will not be included and it is thus likely that medical device companies will need to rethink their business models.

HCPs receiving sponsorships from pharmaceutical and medical device companies for participation in events outside of Denmark must notify the Danish Health and Medicines Authority of the sponsorship. The Danish Health and Medicines Authority will then make the information public.

The companies' duties are:

  • not to provide unlawful economic benefits to HCPs; and
  • to inform the HCPs of the HCPs' duty to notify the Authority of sponsorships relating to events taking place outside of Denmark. Companies failing to observe this requirement may be subject to fines.

Join our LinkedIn group

Four new partners at Horten

16 January 2018

With effect from 1 January 2018, Horten appointed Christian Tullberg, Kristoffer Westberg, Christina Steen and Niels Jørgen Oggesen as partners.

Self-selection of OTC drugs

9 January 2018

From 1 January 2018, OTC drugs may be available for self-selection, which means that pharmacies and retailers may sell certain OTC drugs from shop areas and not only at the counter.

New Managing Partner at Horten

2 January 2018

Finn Schwarz, Attorney and Partner, has been appointed Managing Partner of Horten Law Firm as of 1 January 2018.

Judgment in the Coty case: Prohibition against use of third party's online platform was not unlawful

12 December 2017

On 6 December 2017, the European Court of Justice ruled that cosmetics manufacturer Coty's prohibition against internet sale via third parties was not unlawful.

New recommendations for the implementation of the Clinical Trial Regulation

14 November 2017

The European Commission has recently published three recommendations for the implementation of regulation (EU) No 536/2014 on clinical trials on medical products for human use (the Clinical Trial Regulation).

New verification system in the fight against falsified medicinal products

13 October 2017

On 9 February 2019, a new verification system will come into force making it possible to verify a medicinal product's authenticity and prevent the flow of falsified medicinal products within the legal supply chain.

New executive order regarding cannabis out for consultation

3 October 2017

Last week, a draft executive order on import of cannabis starting materials and the subsequent manufacturing of cannabis intermediate products went out for consultation.

Green Tech Challenge 2017

27 September 2017

Horten supports the Green Tech Challenge with a team of advisors and a financial contribution. The Green Tech Challenge supports a number of selected Nordic tech companies with a strong sustainable agenda to optimise their businesses.

Compliance: E-leaning in competition law

20 September 2017

Horten now offers e-learning in competition law tailored to each company.

European ip rights in Great Britain after Brexit

19 September 2017

Great Britain's exit from the EU will create uncertainty for both British and EU27 companies in relation to the extent and protection of intellectual property rights in Great Britain. It is therefore of great interest and importance to clarify the consequences of Great Britain’s exit and how to handle them.

The edtech company Labster announces Series A investment

7 September 2017

Labster recently announced a Series A investment round of $ 10 million with the participation of the venture capital funds Balderton Capital and Northzone.

The Maritime and Commercial High Court states: Hästens' trademark infringed

18 August 2017

The Maritime and Commercial High Court has ruled that Hästens Sängar AB’s blue check pattern is a (well-known) trademark in Denmark. The manufacturer Nordicform AS, Magasin and a number of other distributors have thereby infringed Hästens’ trademark rights and violated the Danish Marketing Practices Act by selling bedclothes with the blue check pattern, and they must pay compensation.

Still waiting for a European Patent Court

20 June 2017

The agreement concerning the European Patent Court is once again delayed. The agreement concerning the establishment of a so-called unitary patent and a joint patent court was planned to come into force in December 2017, but this will presumably not be the case.

Horten advances in new Chambers and Legal 500 rankings

19 April 2017

In 2017, the leading international ranking agencies, Legal 500 and Chambers, are once again ranking Horten among the best law firms in Denmark.

Comparative markets - supermarkets and hypermarkets

9 March 2017

The CJEU recently issued its ruling in case C-562/15 on comparative advertising comparing prizes between shops of different sizes and formats.

New action plan for the implementation of the regulation on data protection

30 January 2017

The Article 29 group has adopted a new action plan listing which subjects the group will prioritise in 2017 to ensure an effective implementation of the regulation on data protection.

Data protection officer – who, when, what?

12 January 2017

The so-called Article 29 group has adopted a set of guidelines covering data protection officers, which will provide more clarity with regard to the data protection officer's assignments, position and liability.

Global Leaders in Law appoints Horten as exclusive partner for Denmark

10 January 2017

Global Leaders in Law, the leading global general counsel forum based in London, and Horten has announced partnership. Appointed as a global bronze partner, Horten will sponsor the activities of Global Leaders in Law in 2017.

Greenland adopts personal data act

22 November 2016

From 1 December 2016, the Personal Data Act became effective in Greenland at the request of the Greenland Home Rule. The Act replaces the data protection legislation from 1978, which has applied in Greenland until now.

Horten on two committees at the Confederation of Danish Industry, DI

3 October 2016

DI has re-appointed Søren Hornbæk Svendsen as member of the Energy and Climate Policy Committee and Nina Henningsen as member of the Media Policy Committee.

Internet media under pressure because of new EU ruling

15 September 2016

The latest ruling on hyper links and copyright confirms previous case law and adds a new rule of presumption, which may threaten the existence of some Internet media.

Easier for customs to stop copied products

14 September 2016

According to new EU rules, the owner of a product must, in the event of a trademark dispute, prove that the product is not a copy.

Circle K wins over OK in legal action concerning a new logo - Horten assisted Circle K

25 August 2016

Horten has assisted Circle K in a legal action against OK. OK claimed that Circle K's new logo infringed the company's trademark rights to OK and was therefore contrary to the Trademark Act.

New rules on trade secrets in the pipeline

27 June 2016

At the end of 2013, the European Commission presented a draft directive on the legal protection of trade secrets. After more than two years' negotiations between the European Commission, the European Parliament and the Member States, political agreement was reached on a final draft shortly before Christmas. The revised directive was finally adopted by the Council on 26 May 2016.

Horten is promoted to the gold tier for 2016 in IAM Patent 1000

8 June 2016

Glowing reports from peers and patrons see Horten promoted to the gold tier for 2016. It is “a force to be reckoned with in high-stakes litigation”.

Eckes-Granini acquires Rynkeby Foods A/S

19 May 2016

German-based Eckes-Granini Group GmbH (‘Eckes-Granini’), the leading producer of branded fruit-based beverages in Europe, has on 18 May 2010 acquired Rynkeby Foods A/S.

New ratings from the international reference book Legal 500

4 May 2016

There are several good news for Horten in the new rankings, among these to new Tier 1-ratings in Media & entertainment and Telecoms.

Final adoption of the new personal data regulation

14 April 2016

The European Parliament has adopted the new personal data regulation together with the rest of the data protection reform.

International women lawyers discuss the future of the legal profession

6 April 2016

Horten participates when 150 lawyers from all over the world meet in Berlin on 7-8 April under the headline "Law in a changing world – how women can contribute to innovation of the legal profession".

Horten Corporate Day 2016 - Danish companies at the forefront

18 March 2016

At Horten's Corporate Day 2016 on 16 March, Danish and foreign executives and experts gave their views on the trends and opportunities of the Danish business sector. Horten will repeat the success next year with Horten Corporate Day 2017.

The Eastern High Court: Pressalit infringed Tivoli's trademark and breached the licence agreement

2 March 2016

In January 2016, the Eastern High Court ruled in the appeal proceedings between Tivoli A/S and Pressalit Group A/S.

The Eastern High Court: Label infringes design right

9 February 2016

Horten represented the manufacturer of a diaper pail, Sangenic, and the High Court ruled that the use of a picture of the design-protected pail constituted an infringement of the design right.

New online dispute portal and requirements for web shops

19 January 2016

In the future, all Danish and EU web shops must link to the pan-European online dispute portal ODR (Online Dispute Resolution). ODR will be available from 15 February 2016.

New survey: Horten among the best within trademarks

18 January 2016

The recognised international magazine World Trademark Review (WTR) elects Horten as one of the country's leading advisers within trademark law.